245 related articles for article (PubMed ID: 17937985)
1. Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility.
Wang X; Chakrabarti PP; Ognyanov VI; Pettus LH; Tamir R; Tan H; Tang P; Treanor JJ; Gavva NR; Norman MH
Bioorg Med Chem Lett; 2007 Dec; 17(23):6539-45. PubMed ID: 17937985
[TBL] [Abstract][Full Text] [Related]
2. Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.
Wang HL; Katon J; Balan C; Bannon AW; Bernard C; Doherty EM; Dominguez C; Gavva NR; Gore V; Ma V; Nishimura N; Surapaneni S; Tang P; Tamir R; Thiel O; Treanor JJ; Norman MH
J Med Chem; 2007 Jul; 50(15):3528-39. PubMed ID: 17585751
[TBL] [Abstract][Full Text] [Related]
3. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.
Doherty EM; Fotsch C; Bannon AW; Bo Y; Chen N; Dominguez C; Falsey J; Gavva NR; Katon J; Nixey T; Ognyanov VI; Pettus L; Rzasa RM; Stec M; Surapaneni S; Tamir R; Zhu J; Treanor JJ; Norman MH
J Med Chem; 2007 Jul; 50(15):3515-27. PubMed ID: 17585750
[TBL] [Abstract][Full Text] [Related]
4. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
[TBL] [Abstract][Full Text] [Related]
5. Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists.
Stec MM; Bo Y; Chakrabarti PP; Liao L; Ncube M; Tamayo N; Tamir R; Gavva NR; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2008 Sep; 18(18):5118-22. PubMed ID: 18722118
[TBL] [Abstract][Full Text] [Related]
6. 4-Aminopyrimidine tetrahydronaphthols: a series of novel vanilloid receptor-1 antagonists with improved solubility properties.
Doherty EM; Retz D; Gavva NR; Tamir R; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2008 Mar; 18(6):1830-4. PubMed ID: 18299195
[TBL] [Abstract][Full Text] [Related]
7. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.
Norman MH; Zhu J; Fotsch C; Bo Y; Chen N; Chakrabarti P; Doherty EM; Gavva NR; Nishimura N; Nixey T; Ognyanov VI; Rzasa RM; Stec M; Surapaneni S; Tamir R; Viswanadhan VN; Treanor JJ
J Med Chem; 2007 Jul; 50(15):3497-514. PubMed ID: 17585749
[TBL] [Abstract][Full Text] [Related]
8. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
Ognyanov VI; Balan C; Bannon AW; Bo Y; Dominguez C; Fotsch C; Gore VK; Klionsky L; Ma VV; Qian YX; Tamir R; Wang X; Xi N; Xu S; Zhu D; Gavva NR; Treanor JJ; Norman MH
J Med Chem; 2006 Jun; 49(12):3719-42. PubMed ID: 16759115
[TBL] [Abstract][Full Text] [Related]
9. 1,2-diamino-ethane-substituted-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepines as TRPV1 antagonists with improved properties.
Lebsack AD; Rech JC; Branstetter BJ; Hawryluk NA; Merit JE; Allison B; Rynberg R; Buma J; Rizzolio M; Swanson N; Ao H; Maher MP; Herrmann M; Freedman J; Scott BP; Luo L; Bhattacharya A; Wang Q; Chaplan SR; Wickenden AD; Breitenbucher JG
Bioorg Med Chem Lett; 2010 Dec; 20(23):7142-6. PubMed ID: 20932750
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship (SAR) investigations of substituted imidazole analogs as TRPV1 antagonists.
Gore VK; Ma VV; Tamir R; Gavva NR; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2007 Nov; 17(21):5825-30. PubMed ID: 17851073
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.
Tamayo N; Liao H; Stec MM; Wang X; Chakrabarti P; Retz D; Doherty EM; Surapaneni S; Tamir R; Bannon AW; Gavva NR; Norman MH
J Med Chem; 2008 May; 51(9):2744-57. PubMed ID: 18386885
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides.
Doherty EM; Fotsch C; Bo Y; Chakrabarti PP; Chen N; Gavva N; Han N; Kelly MG; Kincaid J; Klionsky L; Liu Q; Ognyanov VI; Tamir R; Wang X; Zhu J; Norman MH; Treanor JJ
J Med Chem; 2005 Jan; 48(1):71-90. PubMed ID: 15634002
[TBL] [Abstract][Full Text] [Related]
13. Identification and synthesis of 2,7-diamino-thiazolo[5,4-d]pyrimidine derivatives as TRPV1 antagonists.
Lebsack AD; Branstetter BJ; Hack MD; Xiao W; Peterson ML; Nasser N; Maher MP; Ao H; Bhattacharya A; Kansagara M; Scott BP; Luo L; Rynberg R; Rizzolio M; Chaplan SR; Wickenden AD; Guy Breitenbucher J
Bioorg Med Chem Lett; 2009 Jan; 19(1):40-6. PubMed ID: 19038548
[TBL] [Abstract][Full Text] [Related]
14. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
15. Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain.
Culshaw AJ; Bevan S; Christiansen M; Copp P; Davis A; Davis C; Dyson A; Dziadulewicz EK; Edwards L; Eggelte H; Fox A; Gentry C; Groarke A; Hallett A; Hart TW; Hughes GA; Knights S; Kotsonis P; Lee W; Lyothier I; McBryde A; McIntyre P; Paloumbis G; Panesar M; Patel S; Seiler MP; Yaqoob M; Zimmermann K
J Med Chem; 2006 Jan; 49(2):471-4. PubMed ID: 16420034
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists.
Xi N; Bo Y; Doherty EM; Fotsch C; Gavva NR; Han N; Hungate RW; Klionsky L; Liu Q; Tamir R; Xu S; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2005 Dec; 15(23):5211-7. PubMed ID: 16203144
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans.
Gavva NR; Treanor JJ; Garami A; Fang L; Surapaneni S; Akrami A; Alvarez F; Bak A; Darling M; Gore A; Jang GR; Kesslak JP; Ni L; Norman MH; Palluconi G; Rose MJ; Salfi M; Tan E; Romanovsky AA; Banfield C; Davar G
Pain; 2008 May; 136(1-2):202-10. PubMed ID: 18337008
[TBL] [Abstract][Full Text] [Related]
19. Analgesic potential of TRPV1 antagonists.
Kym PR; Kort ME; Hutchins CW
Biochem Pharmacol; 2009 Aug; 78(3):211-6. PubMed ID: 19481638
[TBL] [Abstract][Full Text] [Related]
20. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation.
Klionsky L; Tamir R; Holzinger B; Bi X; Talvenheimo J; Kim H; Martin F; Louis JC; Treanor JJ; Gavva NR
J Pharmacol Exp Ther; 2006 Oct; 319(1):192-8. PubMed ID: 16844842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
